Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCD | O00767 | 9/20 | 0.41 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.39 |
| ▸ | ACKR3 | P25106 | 1/20 | 0.38 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.37 |
| ▸ | PSMD14 | O00487 | 1/20 | 0.36 |
| ▸ | STAMBP | O95630 | 1/20 | 0.36 |
| ▸ | COPS5 | Q92905 | 1/20 | 0.36 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.36 |
| ▸ | ACHE | P22303 | 1/20 | 0.36 |
| ▸ | GSK3B | P49841 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1767807 | 0.91 | SCD (0.49) | SCDMAPK1HDAC1KLKB1 | |
| SCHEMBL18121968 | 0.91 | SCD (0.42) | SCDROCK2ACKR3HDAC1PSMD14 | |
| SCHEMBL1767456 | 0.87 | HDAC1 (0.49) | SCDROCK2HDAC1 | |
| SCHEMBL1767520 | 0.87 | SCD (0.50) | SCDROCK2HDAC1 | |
| SCHEMBL1767539 | 0.86 | ROCK2 (0.42) | SCDROCK2HDAC1KLKB1ACHE | |
| SCHEMBL1767507 | 0.85 | SCD (0.57) | SCD | |
| SCHEMBL1767553 | 0.85 | SCN3A (0.46) | SCDSCN9AHDAC1KLKB1 | |
| SCHEMBL1767389 | 0.85 | SCD (0.50) | SCDHDAC1KLKB1 | |
| SCHEMBL1767533 | 0.83 | SCD (0.45) | SCDROCK2HDAC1KLKB1ACHE | |
| SCHEMBL1767401 | 0.83 | SCD (0.45) | SCDROCK2SCN9AKLKB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160289191-A1 | ORGANIC COMPOUNDS | XENON PHARMACEUTICALS INC. (CA) | 2016-10-06 | — | — | US | claimed |
| US-20110105530-A1 | ORGANIC COMPOUNDS | XENON PHARMACEUTICALS INC. (CA) | 2011-05-05 | — | — | US | claimed |
| US-20160289191-A1 | ORGANIC COMPOUNDS | XENON PHARMACEUTICALS INC. (CA) | 2016-10-06 | — | — | US | disclosed |
| US-20160289191-A1 | ORGANIC COMPOUNDS | XENON PHARMACEUTICALS INC. (CA) | 2016-10-06 | — | — | US | disclosed |
| US-20160289191-A1 | ORGANIC COMPOUNDS | XENON PHARMACEUTICALS INC. (CA) | 2016-10-06 | — | — | US | disclosed |
| US-9187426-B2 | Organic compounds | NOVARTIS AG (CH) | 2015-11-17 | — | — | US | disclosed |
| US-9187426-B2 | Organic compounds | NOVARTIS AG (CH) | 2015-11-17 | — | — | US | disclosed |
| US-20110105530-A1 | ORGANIC COMPOUNDS | XENON PHARMACEUTICALS INC. (CA) | 2011-05-05 | — | — | US | disclosed |
| US-20110105530-A1 | ORGANIC COMPOUNDS | XENON PHARMACEUTICALS INC. (CA) | 2011-05-05 | — | — | US | disclosed |
| WO-2009156484-A2 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2009-12-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110105530-A1 | ORGANIC COMPOUNDS | SCD, SCD5, FADS2 | SCD 1/4885ROCK2 3930/4885ACKR3 4421/4885 |
| US-20160289191-A1 | ORGANIC COMPOUNDS | SCD, SCD5, FADS2 | SCD 1/4885ROCK2 3930/4885ACKR3 4421/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.